Primo Brands Corporation heads into the back half of 2026 with analysts raising targets, short sellers quietly retreating, and the stock still trading at a meaningful discount to where the Street thinks it belongs.
The most telling signal this week came from the analyst community. RBC Capital's Nik Modi lifted his target to $31 from $28 on August 7 — the most aggressive call on the stock right now — while Barclays raised its own target to $29 from $27 the same day, keeping an Overweight rating. That follows a JPMorgan target raise to $29 in mid-July. The pattern is consistent: bulls are recalibrating upward after last week's Q2 print, which pushed the stock up roughly 2.7% on the day of release. The consensus mean target now sits at $30.36, roughly 29% above the current price of $23.57. Even after a 3.8% weekly gain, the gap between where PRMB trades and where analysts think it should be remains wide.
Short positioning reinforces the constructive read, though with nuance. Bears have pulled back materially — SI has dropped 23% over the past month, falling from above 37 million shares to around 28.8 million, and now represents 7.8% of the free float. That is still a meaningful short book, but the direction of travel is firmly lower. Borrowing costs have also fallen, down roughly 18% on the week to just 0.41% — cheap and easy to access. Availability is loose at 327%, meaning there are more than three shares available to borrow for every one currently on loan. Nothing in the lending market is putting pressure on existing shorts. The ORTEX short score, at 65.9, has been drifting lower through the week from a recent peak near 67.3 — a modest but directionally consistent easing of bearish conviction.
Options positioning has shifted more defensively in recent days, and it is worth noting the contrast. The put/call ratio has jumped to 0.25, well above its 20-day average of 0.15, and the z-score has climbed to 1.3 — not extreme, but the highest level seen in several weeks. Through most of July the PCR was running below 0.09, so the recent tick-up is notable. This looks less like outright fear and more like incremental hedging after a stock that has risen 42% year-to-date. Context matters: even at 0.25, the PCR is far from its 52-week high of 1.02, and call open interest still dominates the book.
On the ownership side, the institutional structure is anchored by One Rock Capital Partners, which holds 32% of shares and did not change its position in the most recent filing. FMR (Fidelity) added 1.78 million shares through June, and Columbia Management added 1.5 million over the same period — both meaningful additions from sizable holders. Vanguard's Capital Management arm reported a full new position of 12.3 million shares as of June 30, though this may reflect a reclassification or fund restructure rather than open-market buying. Insider data is stale (last recorded trade was January 2026) and not actionable here.
The next scheduled earnings date is November 5. Between now and then, the key variables to watch are whether short sellers continue trimming at the pace seen over the past month, and whether the analyst target-raise cycle translates into actual multiple expansion — with EV/EBITDA running at 9.1x and a PE near 16.8x, the stock is not expensive relative to the upside the Street is pricing in.
See the live data behind this article on ORTEX.
Open PRMB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
